BAY 43-9006, Free base

• CAT Number: A000154
• CAS Number: 284461-73-0
• Molecular Formula: C₂₁H₁₆ClF₃N₄O₃
• Molecular Weight: 464.82
• Purity: ≥95%
• Synonyms: BAY 43-9006
• Target: PDGFR
• Solubility: >23.3mg/mL in DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
• InChI: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
• InChIKey: MLDQJTXFUGDVEO-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

BAY 43-9006 Free base（Cat No.:A000154）is a multikinase inhibitor that targets several key enzymes involved in tumor growth and angiogenesis, including RAF kinase, VEGFR, and PDGFR. By inhibiting these kinases, Sorafenib disrupts tumor cell proliferation and angiogenesis, leading to reduced tumor growth and metastasis. It has been approved for the treatment of various cancers, including advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Sorafenib is widely used in oncology research to study its effects on signaling pathways related to tumor development, making it a significant agent in targeted cancer therapy.